Cargando…

Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium

Severe asthma is associated with substantial morbidity and mortality. Therapies must be maximized to gain control of a patient's severe asthma; however, avoiding overtreatment is also important. The mainstays of asthma maintenance treatment are inhaled corticosteroids (ICS) and long-acting β(2)...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hamelmann, Eckard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220412/ https://www.ncbi.nlm.nih.gov/pubmed/30474042 http://dx.doi.org/10.1155/2018/7473690

Ejemplares similares

Corrigendum to “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium”
por: Hamelmann, Eckard
Publicado: (2019)

Long-acting muscarinic antagonists for the treatment of asthma in children—a new kid in town
por: Hamelmann, Eckard
Publicado: (2018)

Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma
por: Aalbers, René, et al.
Publicado: (2017)

A comparison of tiotropium, long-acting β(2)-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma
por: Vogelberg, Christian, et al.
Publicado: (2020)

Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide
por: Price, David, et al.
Publicado: (2015)

Efficacy and Safety of Tiotropium in Children and Adolescents
por: Hamelmann, Eckard, et al.
Publicado: (2018)

A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma
por: Hamelmann, Eckard, et al.
Publicado: (2017)

Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
por: Busse, William W., et al.
Publicado: (2016)

Asthma exacerbations and worsenings in patients aged 1–75 years with add-on tiotropium treatment
por: Mark FitzGerald, J., et al.
Publicado: (2020)

Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?
por: Cazzola, Mario, et al.
Publicado: (2023)

The role of tiotropium in the management of asthma
por: Park, Heung-Woo
Publicado: (2012)

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Novel long‐acting antagonists of muscarinic ACh receptors
por: Randáková, Alena, et al.
Publicado: (2018)

The evolving role of tiotropium in asthma
por: McIvor, Emma R, et al.
Publicado: (2017)

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
por: Chapman, Kenneth R, et al.
Publicado: (2014)

Erratum to: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Addressing the risk domain in the long‐term management of pediatric asthma
por: Hamelmann, Eckard, et al.
Publicado: (2019)

Expression of Muscarinic Receptors and the Effect of Tiotropium Bromide in Aged Mouse Model of Chronic Asthma
por: Kang, Ji Young, et al.
Publicado: (2019)

Comparative Responses in Lung Function Measurements with Tiotropium in Adolescents and Adults, and Across Asthma Severities: A Post Hoc Analysis
por: Halpin, David M. G., et al.
Publicado: (2020)

Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients
por: Vogelberg, Christian, et al.
Publicado: (2019)

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
por: D’Urzo, Anthony D, et al.
Publicado: (2018)

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
por: Ora, Josuel, et al.
Publicado: (2020)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
por: Yamada, Hideyasu, et al.
Publicado: (2018)

Future perspectives of anticholinergics for the treatment of asthma in adults and children
por: Buhl, Roland, et al.
Publicado: (2019)

Safety of tiotropium in patients with asthma
por: Dusser, Daniel, et al.
Publicado: (2019)

Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma
por: Zhang, Li, et al.
Publicado: (2018)

Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium
por: Katsumata, Mineo, et al.
Publicado: (2022)

The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review
por: Zhou, Ji’an, et al.
Publicado: (2021)

Allergen reduction by nightly temperature controlled laminar airflow (TLA) decreases exacerbation rate in severe allergic asthma
por: Schauer, Uwe, et al.
Publicado: (2015)

Muscarinic Receptor Agonists and Antagonists
por: Broadley, Kenneth J., et al.
Publicado: (2001)

Barriers to achieving asthma control in adults: evidence for the role of tiotropium in current management strategies
por: Jenkins, Christine
Publicado: (2019)

The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review
por: Calzetta, Luigino, et al.
Publicado: (2022)

Forced Expiratory Flow (FEF(25–75%)) as a Clinical Endpoint in Children and Adolescents with Symptomatic Asthma Receiving Tiotropium: A Post Hoc Analysis
por: Szefler, Stanley J., et al.
Publicado: (2020)

Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management
por: Kaplan, Alan, et al.
Publicado: (2020)

Tiotropium in asthma: back to the future of anticholinergic treatment
por: Bonini, Matteo, et al.
Publicado: (2017)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Tiotropium for the Treatment of Asthma: Patient Selection and Perspectives
por: Chari, V. Madhu, et al.
Publicado: (2018)

Long-acting muscarinic antagonists vs. long-acting β (2) agonists in COPD exacerbations: a systematic review and meta-analysis
por: Maia, Israel Silva, et al.
Publicado: (2017)

A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β(2)-Agonist (LABA) Combinations in COPD
por: Sion, Katya Y. J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a2url7dv6s78dooevmbldihjdk